Ethena Labs adds bitcoin as USDe backing asset
Ethena Labs is backing its USDe synthetic dollar with bitcoin. The move will enable USDe to “scale significantly,” as traders embrace bitcoin, the protocol said.
The decentralized finance (DeFi) protocol said Thursday in a series of posts on X that backing USDe with bitcoin will enable its dollar-pegged token to scale by a factor of more than 2.5, as well as make its products safer for traders. The move comes as bitcoin derivative markets outpace their ether-based equivalents.
“As Ethena scales closer towards $10bn this provides a more robust backing, and ultimately a safer product for users,” the protocol said Thursday. USDe’s current supply is worth roughly $2 billion, it added.
Ethena also pointed to bitcoin's superior liquidity and duration profile for delta hedging compared to liquid staking tokens as a factor in its decision to add bitcoin as a backing asset.
Until now, USDe has been backed exclusively by staked ether (ETH), Ethena Labs’ website shows. Token holders are showing stronger interest in trading bitcoin, however.
Bitcoin open interest surged 150% to $25 billion in the past year, leading to a more than doubling of USDe's capacity to scale, Ethena said. Meanwhile, ether's open interest grew just 100% to $10 billion during the same period, according to data the protocol cited.
Bitcoin's comparatively strong demand comes amid a spectacular run-up in the virtual token's speculative value. Bitcoin is trading at $68,384 at the time of writing, The Block's price data shows, up 4% over the past 24 hours.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.
